aggregate development and commercialization milestones description.

No definition available.

Name:	lxeo_AggregateDevelopmentAndCommercializationMilestonesDescription
Namespace Prefix:	lxeo_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Commercialization milestones due.

+ References

No definition available.

+ Details

Name:	lxeo_CommercializationMilestonesDue
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development and commercialization milestones due.

+ References

No definition available.

+ Details

Name:	lxeo_DevelopmentAndCommercializationMilestonesDue
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development and regulatory milestones due.

+ References

No definition available.

+ Details

Name:	lxeo_DevelopmentAndRegulatoryMilestonesDue
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement termination notice period.

+ References

No definition available.

+ Details

Name:	lxeo_LicenseAgreementTerminationNoticePeriod
Namespace Prefix:	lxeo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone received

+ References

No definition available.

+ Details

Name:	lxeo_MilestoneReceived
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of license agreements.

+ References

No definition available.

+ Details

Name:	lxeo_NumberOfLicenseAgreements
Namespace Prefix:	lxeo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of research agreements.

+ References

No definition available.

+ Details

Name:	lxeo_NumberOfResearchAgreements
Namespace Prefix:	lxeo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

One time up front non refundable fees.

+ References

No definition available.

+ Details

Name:	lxeo_OneTimeUpFrontNonRefundableFees
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payment of annual data transfer fee.

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfAnnualDataTransferFee
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of annual license maintenance fees

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfAnnualLicenseMaintenanceFees
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment Of Clinical And Regulatory Milestone.

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfClinicalAndRegulatoryMilestone
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of development milestone.

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfDevelopmentMilestone
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of license issue fee and initial data transfer fee

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfLicenseIssueFeeAndInitialDataTransferFee
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of one time up front non refundable fee.

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfOneTimeUpFrontNonRefundableFee
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment of regulatory milestones

+ References

No definition available.

+ Details

Name:	lxeo_PaymentOfRegulatoryMilestones
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payment to additional data transfer process.

+ References

No definition available.

+ Details

Name:	lxeo_PaymentToAdditionalDataTransferProcess
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research agreement termination notice period.

+ References

No definition available.

+ Details

Name:	lxeo_ResearchAgreementTerminationNoticePeriod
Namespace Prefix:	lxeo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research agreements term.

+ References

No definition available.

+ Details

Name:	lxeo_ResearchAgreementsTerm
Namespace Prefix:	lxeo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and development Aarrangement, ontract to perform for others, dditional costs incurred.

+ References

No definition available.

+ Details

Name:	lxeo_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalCostsIncurred
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Specific clinical and regulatory milestones due.

+ References

No definition available.

+ Details

Name:	lxeo_SpecificClinicalAndRegulatoryMilestonesDue
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	lxeo_UpfrontCashPayment
Namespace Prefix:	lxeo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Date when acquirer obtains control of acquiree in business combination, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 25
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479405/805-10-25-7

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 25
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479405/805-10-25-6

+ Details

Name:	us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of voting equity interest acquired in business combination.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-42

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:	us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

+ Details

Name:	us-gaap_DebtConversionOriginalDebtAmount1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The fair value of notes issued in noncash investing and financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:	us-gaap_NotesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of common shares issuable upon conversion of preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:	us-gaap_PreferredStockConvertibleSharesIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lxeo_SteliosTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_AdverumLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=lxeo_AdverumBiotechnologiesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_CornellLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=lxeo_CornellUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=lxeo_SeriesAConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_FirstCornellLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_SecondCornellLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_TwoPortfoliosMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lxeo_ThirdPortfolioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_ThirdCornellLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_SecondAmendmentToTheThirdCornellLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_FirstUcsdLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_SecondUcsdLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_ThirdUcsdLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_AmendedFirstUcsdAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_UcsdSponsoredResearchAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_AbiomedAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=lxeo_AmendedUCSDSponsoredResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License, Acquisition, Research and Collaboration and Sponsored Research Agreements - Additional Information (Details)												1 Months Ended	3 Months Ended
	Nov. 14, 2025 USD ($)	Apr. 21, 2024 USD ($)	Apr. 19, 2024 USD ($)	Apr. 13, 2024 USD ($)	Dec. 03, 2021 USD ($) IntegerItem	Oct. 04, 2021 USD ($)	Jul. 16, 2021 USD ($)	Jan. 25, 2021 USD ($)	Aug. 06, 2020 USD ($)	May 28, 2020 USD ($) IntegerItem	Apr. 23, 2020 USD ($)	Nov. 30, 2020 USD ($) shares	Mar. 31, 2026 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 17, 2025 USD ($)	Nov. 07, 2023 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses													$ 15,703,000	$ 17,171,000
Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone paid													6,000,000
Asset acquisition date of acquisition							Jul. 16, 2021
Asset acquisition percentage of outstanding stock acquisition							100.00%
Payment to selling shareholders															$ 6,000,000
Milestone received													$ 1,300,000
Maximum \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to selling shareholders							$ 12,500,000
Adverum License Agreement \| Adverum Biotechnologies Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time up-front non-refundable fee paid								$ 7,500,000									$ 7,500,000
Development milestone paid																	$ 3,500,000
Royalty payments description													The Company is obligated to pay Adverum tiered royalties ranging from high single-digits to sub teens based on annual aggregate worldwide net sales of Products (as defined in the Adverum Agreement).
Research and development expenses													$ 0
License agreement termination notice period								120 days
Adverum License Agreement \| Adverum Biotechnologies Inc \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and regulatory milestones due								$ 17,500,000
Commercialization milestones due								$ 49,000,000
Cornell License Agreements \| Cornell University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement termination notice period										90 days
Number of license agreements \| IntegerItem										2
Upfront payment in cash										$ 300,000
Notes issued										1,300,000
Notes with outstanding principal exchanged												$ 1,300,000
Cornell License Agreements \| Cornell University \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Converted shares into common stock \| shares																				126,258
Cornell License Agreements \| Cornell University \| Series A Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued on debt exchanged \| shares												1,337,610
First Cornell License Agreements \| Cornell University \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Specific clinical and regulatory milestones due										8,400,000
Second Cornell License Agreements \| Cornell University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Clinical and regulatory milestone paid																		$ 100,000
Second Cornell License Agreements \| Cornell University \| Maximum \| Two Portfolios
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Specific clinical and regulatory milestones due										4,300,000
Second Cornell License Agreements \| Cornell University \| Maximum \| Third Portfolio
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Specific clinical and regulatory milestones due										$ 600,000
Third Cornell License Agreements \| Cornell University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement termination notice period		90 days
License fee and initial data transfer fee		$ 600,000
Annual data transfer fee		50,000
Third Cornell License Agreements \| Cornell University \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual license maintenance fees		2,500
Third Cornell License Agreements \| Cornell University \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commercialization milestones due		100,000,000
Annual license maintenance fees		25,000
Regulatory milestone to be paid		$ 2,100,000
Second Amendment To The Third Cornell License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses													400,000	30,000
Payment to additional data transfer process																			$ 100,000
Payment to research and development													$ 0	0
First UCSD License Agreement \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time up-front non-refundable fee paid											$ 20,000
First UCSD License Agreement \| Maximum \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and commercialization milestones due											$ 4,800,000
Second UCSD License Agreement \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time up-front non-refundable fee paid	$ 20,000
License agreement termination notice period	60 days								60 days
Second UCSD License Agreement \| Stelios Therapeutics Inc \| Research and Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time up-front non-refundable fees	$ 20,000								$ 20,000
Second UCSD License Agreement \| Maximum \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and commercialization milestones due	$ 2.4
Third UCSD License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional costs incurred for research				$ 600,000
Research agreements term				2 years
Research agreement termination notice period				30 days
Costs incurred for research				$ 700,000
Third UCSD License Agreement \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time up-front non-refundable fee paid						$ 20,000
License agreement termination notice period						60 days
Development and commercialization milestones description													the Company to pay aggregate development and commercialization milestones of up to $4.0 million, and low- to mid-single digit royalties based on aggregate net sales
Third UCSD License Agreement \| Stelios Therapeutics Inc \| Research and Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone paid																$ 100,000
One-time up-front non-refundable fees						$ 20,000
Third UCSD License Agreement \| Maximum \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and commercialization milestones due						$ 4,000,000
Amended First UCSD Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs incurred for research			$ 700,000
UCSD Sponsored Research Agreements \| Stelios Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses													$ 0	34,000
Number of research agreements \| IntegerItem					2
Research agreements term					2 years
Research agreement termination notice period					30 days
Costs incurred for research					$ 5,600,000
Payment to research and development													500,000	$ 100,000
Abiomed Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses													0
Payment to research and development													0
Amended UCSD Sponsored Research Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses													5,700,000
Payment to research and development													$ 5,700,000